Recent research have focused on the intersection of glucagon-like peptide-1|GIP|GCGR activator therapies and DA signaling. While GIP activators are commonly employed for treating type 2 diabetes mellitus, their potential impacts on motivation circuits, specifically governed by DA pathways, are receiving considerable attention. This report provides